---
title: 'Medical Director/Senior Medical Director, Patient Safety & Risk Management at Relay Therapeutics'
canonical: 'https://feeny.ai/job/medical-director-senior-medical-director-patient-safety-risk-management-relay-kq6nb9077wvg'
type: 'job'
last_seen: '2026-10-13'
---

# Medical Director/Senior Medical Director, Patient Safety & Risk Management at Relay Therapeutics

- **Company:** Relay Therapeutics
- **Location:** Cambridge, MA
- **Posted:** 2026-09-23
- **Last confirmed live:** 2026-10-13
- **Apply:** https://job-boards.greenhouse.io/relaytherapeutics/jobs/6200448004

## Job description

The Opportunity:

The Medical Director, Patient Safety & Risk Management at Relay Therapeutics will serve as the Global Medical Safety Lead (GSL) and provides strategic and medical leadership for the safety surveillance and risk management of Relay Therapeutic assigned products throughout the product lifecycle. This role is responsible for the evaluation, interpretation, and communication of safety information; signal detection and management; benefit-risk assessment; and development of risk minimization strategies to ensure patient safety and regulatory compliance. In addition, the GSL will support the medical review of individual case safety reports and safety surveillance activities as needed for assigned Relay Therapeutic products. The GSL will lead the cross functional Safety Management Team in the evaluation  of safety signals and implementation of risk minimization activities for Relay Therapeutic products.

We are seeking  a safety physician, who thrives in a dynamic, agile biotech environment. Reporting to the Executive Director, Patient Safety & Risk Management, this individual serve as a key collaborator and leader in cross functional clinical program teams, including Clinical Development, Clinical Operations, Biostats, Data Management and Regulatory Affairs. The successful candidate will play a critical role in advancing the development of transformative therapies by providing medical safety expertise.

Your Role:

- Direct the planning, preparation, writing and review of safety aggregate reports, including DSUR.
- Train/collaborate and support qualified PSRM staff on medical review, safety surveillance activities and authoring of aggregate reports.
- Provide benefit-risk assessment on potential safety signal or in safety documents/reports and leads product benefit-risk assessment discussions at safety management meetings.
- Lead cross functional safety management team meetings and escalate safety issues including preparing and presenting of safety issue and recommendation to the executive decision-making body.
- Contribute to the development of Investigator Brochures, Protocols, Subject Informed Consent, statistical analysis plans, integrated safety summary, RMP/REMS, and other study related documents
- Support and collaborate with cross functional teams on safety related activities including providing responses to safety related queries from regulatory authorities and IRB/EC.
- Ensure compliance with regulatory guidelines and internal processes and procedures, to be inspection ready and serve as SME in audits and inspections.
- Serve as back-up medical review/sponsor approval of ICSRs and ensure appropriate medical evaluation of individual case safety reports and emerging safety trends.

Your Background:

- MD, DO or medical degree from an accredited medical school and completion of an accredited medical or surgical residency or clinical experience in either academic setting or private practice
- A minimum of drug safety experience 7-10 years in the pharmaceutical industry
- Experience leading cross functional teams and/or projects
- Expertise in analyzing and presenting complex medical-scientific data from broad range of sources required
- Experience providing medical leadership and strategic review of aggregate safety reports (DSUR, PBRER/PSUR) is required
- Knowledge of global risk management planning including RMPs, REMS (Risk Evaluation and Mitigation strategies) and risk minimization strategies required
- Expertise in global regulations governing safety surveillance and risk management
- Prior NDA filing (ISS drafting and review) experience strongly preferred

Estimated Salary Range: [$201,000 - $351,000].

The range provided above is based on what we believe to be a reasonable estimate for this job at the time of posting. Actual base salary will depend on a number of factors, including but not limited to, a candidate’s education, experience, skills and location.

#BP1

## About Relay Therapeutics

Relay Therapeutics is a clinical-stage precision medicines company transforming the drug discovery process with the goal of bringing life-changing therapies to patients. Built on unparalleled insights into protein motion and how this dynamic behavior relates to protein function, we aim to effectively drug protein targets that have previously been intractable, with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Our Dynamo platform integrates an array of leading-edge experimental and computational approaches to provide a differentiated understanding of protein structure and motion to drug these targets. We have built a world-class team of leading experts from each of these disciplines, and they are driven by a deep collaboration at every step of our drug discovery process.

Our team is equal parts fearless and relentless, with a shared passion for working collaboratively in intellectually stimulating environments. If you’re excited by the challenge of putting protein motion at the heart of drug discovery and passionate about making a difference in the lives of patients, join us!

## About Relay Therapeutics

## Company Overview
- **One-liner**: Relay Therapeutics is a clinical-stage precision medicines company that uses its Dynamo® platform to visualize protein motion and drug previously intractable targets, with an initial focus on precision oncology and genetic disease.
- **Entity Type**: Public (NASDAQ: RLAY)
- **Headquarters**: Cambridge, Massachusetts, United States
- **Founded**: 2016
- **Founders**: Not publicly listed as individual founders; the company was launched by Third Rock Ventures.

## Core Business
- **Primary industry/industries**: Biotechnology, Precision Oncology, Genetic Disease Therapeutics
- **Target customers**: Patients with specific cancer mutations (e.g., PI3Kα, FGFR2, NRAS) and rare genetic diseases (e.g., Fabry disease, PROS); partners are healthcare providers, clinical trial sites, and regulatory bodies.
- **Mission or purpose statement**: "We aim to drug the undruggable." The company is laser-focused on bringing life-changing medicines to patients by visualizing protein motion to discover new therapeutics.

## Products & Services
- **Dynamo® Platform**: A proprietary drug discovery platform that integrates long-timescale molecular dynamics (MD) simulations, cryo-electron microscopy (cryo-EM), and other biophysical techniques to visualize protein motion and identify novel drug binding sites. This is the core technology enabling all pipeline programs.
- **Zovegalisib (RLY-2608)**: A clinical-stage, allosteric, pan-mutant and isoform-selective PI3Kα inhibitor. It is designed to overcome the toxicity of orthosteric inhibitors by sparing wild-type PI3Kα. Currently in a Phase 3 trial (ReDiscover-2) for HR+/HER2- PI3Kα-mutated advanced breast cancer and a Phase 1/2 trial for PROS and vascular anomalies.
- **Lirafugratinib (RLY-4008)**: A selective FGFR2 inhibitor. In December 2024, global development and commercialization rights were out-licensed to Elevar Therapeutics.
- **RLY-8161**: A first-in-class, NRAS-selective inhibitor designed to address the liabilities of pan-RAS inhibitors. Currently in a Phase 1/2 trial for NRAS-mutant melanoma and other solid tumors.
- **Fabry Disease Program**: An investigational non-inhibitory chaperone designed to stabilize the αGal enzyme without inhibiting its activity, potentially offering a chronic treatment option for Fabry disease. Currently in IND-enabling studies.

## Market Standing
- **Valuation/Market Cap**: $909.1 million (as of mid-2026) [linkedin.com](https://www.linkedin.com/company/relay-therapeutics-inc.)
- **Key Metric**: Annual Revenue of $15.4 million (pre-commercial, primarily from collaboration/grants) [linkedin.com](https://www.linkedin.com/company/relay-therapeutics-inc.)
- **Total Funding**: $1.8 billion (including IPO and follow-on offerings) [linkedin.com](https://www.linkedin.com/company/relay-therapeutics-inc.)
- **Notable Investors/Partners**: Third Rock Ventures (founding investor), Nextech Invest, Elevar Therapeutics (out-license partner for lirafugratinib).
- **Growth Signals**: Initiation of the Phase 3 ReDiscover-2 trial for zovegalisib in mid-2025; out-license of lirafugratinib to Elevar Therapeutics in December 2024; advancement of RLY-8161 into Phase 1/2 for NRAS-mutant cancers; expansion of the pipeline into genetic diseases (Fabry).

## Competitive Advantages
- **Dynamo® Platform Moat**: The company's core differentiator is its ability to use long-timescale molecular dynamics simulations to visualize protein motion. This allows them to drug targets (like allosteric sites on PI3Kα and NRAS) that are "undruggable" with traditional static-structure approaches.
- **Selectivity & Tolerability**: Their lead asset, zovegalisib, is designed to be a pan-mutant, isoform-selective PI3Kα inhibitor. This selectivity for mutant over wild-type PI3Kα is a key advantage over first-generation orthosteric inhibitors, potentially offering better efficacy and chronic tolerability.
- **First-in-Class Potential**: RLY-8161 is described as the first NRAS-selective inhibitor, addressing a major unmet need in NRAS-mutant cancers by sparing KRAS and HRAS, which are responsible for the toxicity of pan-RAS inhibitors.

## Strategic Focus
- **Advancing Late-Stage Pipeline**: The primary focus is on executing the Phase 3 ReDiscover-2 trial for zovegalisib in breast cancer and expanding its potential in vascular anomalies (PROS).
- **Expanding Pipeline**: Advancing RLY-8161 (NRAS) through Phase 1/2 and moving the Fabry disease program toward clinical trials.
- **Platform Validation**: Continuing to use the Dynamo® platform to discover new drug candidates for previously intractable targets, thereby validating the platform's broader potential beyond current pipeline assets.

## Why Work Here
- **Culture**: The company describes its culture as "highly integrated, collaborative and entrepreneurial." Employees emphasize that the team is "equal parts bright and bold" and that the work is a "personal mission" driven by a desire to help patients. The culture values candor, quirkiness, and sweating the details. [relaytx.com](https://relaytx.com/careers/)
- **Work Environment**: Based in Cambridge, MA (Kendall Square area). The company is on-site/hybrid, typical for a biotech R&D environment. The team is described as "world-class" and "highly integrated."
- **Notable Perks**: The company offers competitive benefits and perks, investing in employee well-being, financial health, and family support. [relaytx.com](https://relaytx.com/careers/)
- **Engineering & Science Culture**: The company emphasizes a highly collaborative environment where computational scientists (cheminformatics, computational architecture) work side-by-side with experimental biologists, chemists, and structural biologists. The focus on "protein motion" creates a unique intellectual challenge.

## Sources
1. [relaytx.com](https://relaytx.com/)
2. [relaytx.com](https://relaytx.com/pipeline/)
3. [relaytx.com](https://relaytx.com/careers/)
4. [linkedin.com](https://www.linkedin.com/company/relay-therapeutics-inc.)
5. [greenhouse.io](http://job-boards.greenhouse.io/relaytherapeutics)

## Other roles at Relay Therapeutics

- [Associate Director, Drug Substance](https://feeny.ai/job/associate-director-drug-substance-relay-therapeutics-cambridge-wg1mp3ks5hhe) — Cambridge, MA
- [Medical Director](https://feeny.ai/job/medical-director-relay-therapeutics-cambridge-dqfwq8bjw6gh) — Cambridge, MA
- [Associate Director, Biostatistics](https://feeny.ai/job/associate-director-biostatistics-relay-therapeutics-cambridge-ykyy55zptr84) — Cambridge, MA
- [Associate Director, Regulatory Project Management](https://feeny.ai/job/associate-director-regulatory-project-management-relay-therapeutics-cambridge-jhp36tb9dz27) — Cambridge, MA
- [Director/Senior Director, Clinical Pharmacology](https://feeny.ai/job/director-senior-director-clinical-pharmacology-relay-therapeutics-cambridge-qg6wd9az23g8) — Cambridge, MA
- [Director, IT Service Delivery and Enterprise Applications](https://feeny.ai/job/director-it-service-delivery-and-enterprise-applications-relay-therapeutics-f9hzr66r1fke) — Cambridge, MA
- [Senior Manager, Clinical Data Management](https://feeny.ai/job/senior-manager-clinical-data-management-relay-therapeutics-cambridge-yf5gq3qx2xbh) — Cambridge, MA
- [Associate Director/Director, CMC Regulatory](https://feeny.ai/job/associate-director-director-cmc-regulatory-relay-therapeutics-cambridge-fxx1zz50mb8r) — Cambridge, MA
- [Medical Science Liaison - Southeast](https://feeny.ai/job/medical-science-liaison-southeast-relay-therapeutics-southeast-d8fmt3fthtgp) — Southeast
- [Senior Manager, Clinical Business Operations](https://feeny.ai/job/senior-manager-clinical-business-operations-relay-therapeutics-cambridge-9c91kbpgewjr) — Cambridge, MA